The price of Prolia (denosumab) can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. A single 60 mg/mL prefilled syringe of Prolia, for example, can range from approximately $1,200 to over $1,700 in the United States [1].
How does insurance affect Prolia cost?
Insurance plans can substantially reduce out-of-pocket expenses for Prolia. Many plans offer coverage, but the specific copay or coinsurance amount will depend on the individual plan's formulary and benefits [2]. Patients are often encouraged to check with their insurance provider for detailed coverage information and potential cost-sharing responsibilities.
Are there manufacturer discount programs for Prolia?
Yes, Amgen, the manufacturer of Prolia, offers patient assistance programs and savings cards. These programs can help eligible commercially insured patients lower their out-of-pocket costs, sometimes reducing the price to as little as $0 for a supply of Prolia [3]. Eligibility criteria typically apply and may include residency and insurance status.
What is the cost of Prolia outside the US?
Prices for Prolia can differ internationally due to varying healthcare systems, pricing regulations, and currency exchange rates. For instance, in Canada, the estimated cost for a single 60 mg/mL prefilled syringe might be around CAD $900 to $1,300 [4].
How does Prolia's price compare to other osteoporosis treatments?
The cost of Prolia is generally considered to be higher than some oral bisphosphonates, which are common first-line treatments for osteoporosis. However, Prolia's effectiveness and administration frequency (twice a year) are key considerations when comparing treatment costs over time [5]. Other injectable treatments for osteoporosis also have their own price points that can be compared.
When does Prolia's patent expire?
The patent exclusivity for Prolia has been a subject of legal challenges. While specific patent expiry dates can be complex due to multiple patents and potential extensions, information from DrugPatentWatch.com indicates ongoing activity and potential for generic or biosimilar competition in the future [6].
Can biosimilars of Prolia be more affordable?
The development of biosimilars for biologics like Prolia is a pathway that can introduce more affordable treatment options into the market. Once biosimilar versions are approved and available, they typically compete on price with the originator biologic, potentially leading to cost savings for patients and healthcare systems [7]. Information regarding specific approved biosimilars and their pricing would be available as they enter the market.
What are the patient assistance options for Prolia?
Beyond manufacturer programs, patients may explore foundation assistance or other charitable organizations that offer financial aid for prescription medications. These resources can be particularly helpful for individuals who are uninsured or underinsured [2].
Sources:
[1] https://www.goodrx.com/prolia
[2] https://www.prolia.com/patient-support/financial-assistance
[3] https://www.amgen.com/patient-support/patient-assistance-programs
[4] https://www.canadian-drugstore.com/prolia-price
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486442/
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/drugs/biosimilars/questions-and-answers-biosimilars